Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Twenty-five years of triptans - a nationwide population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Twenty-five years of triptans - a nationwide population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chronic migraine: Genetics or environment?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Women With Diabetes Are at Increased Relative Risk of Heart Failure Compared to Men: Insights From UK Biobank

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Rodent disease models can play an indispensable role in drug development. Confirming that translationally-relevant disease mechanisms are engaged in such models is a crucial facet of this process. Accordingly, we have validated the role of calcitonin gene-related peptide signaling in a mouse model of glyceryl trinitrate-provoked migraine-like pain and a spontaneous rat model of migraine-like pain by assessing their pharmacological responsiveness to the small molecule calcitonin gene-related peptide receptor antagonist olcegepant, and the humanised monoclonal calcitonin gene-related peptide antibody ALD405.

METHODS: Cutaneous sensitivity to hind paw, and periorbital mechanical stimulation were used as surrogate markers of activation of relevant pain pathways in each respective model. Separate experiments were performed to identify the time-course of treatment response to olcegepant (1 mg/kg i.p.) and ALD405 (10 mg/kg i.p.).

RESULTS: Olcegepant and ALD405 significantly alleviated cutaneous mechanical hypersensitivity in both models compared with corresponding control treatments (saline and IgG control antibody respectively). As expected, the duration of anti-nociceptive action obtained with ALD405 was considerably longer than that associated with olcegepant. Surprisingly, in the spontaneous rat model the onset of action of ALD405 occurred within just 4 hours after administration.

DISCUSSION: The current data clearly show that calcitonin gene-related peptide-mediated signaling is critically involved in the manifestation of cutaneous hypersensitivity in distinct rodent models of migraine-like pain and emphasise their translational relevance. Moreover, the unexpected rapidity of onset observed for ALD405 supports i) a probable site of action outside the blood-brain barrier, and ii) a potential clinical utility of specific monoclonal calcitonin gene-related peptide antibodies in the abortive treatment of migraine.

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume39
Issue number14
Pages (from-to)1827-1837
Number of pages11
ISSN0333-1024
DOIs
Publication statusPublished - 2019

ID: 58916792